62
Participants
Start Date
November 13, 2018
Primary Completion Date
February 23, 2024
Study Completion Date
February 23, 2024
MEN1611
MEN1611 oral dose administered twice daily for a continuous 28-day cycle
Trastuzumab
Trastuzumab solution for infusion administered weekly via IV
Fulvestrant
Fulvestrant solution for injection administered monthly via IM (only for HR-positive postmenopausal women)
Holy Cross Hospital Inc., Fort Lauderdale
Detroit Clinical Research Center, Farmington Hills
Washington University, St Louis
Cliniques Universitaires Saint-Luc, Brussels
Institut Jules Bordet, Brussels
UZ Leuven, Leuven
Centre Georges François Leclerc, Dijon
Centre Oscar Lambret, Lille
Institut Régional du Cancer de Montpellier, Montferrier-sur-Lez
ICO - Site René Gauducheau, Saint-Herblain
Institut Claudius Regaud Oncopole, Toulouse
Institut Gustave Roussy, Villejuif
Azienda Ospedaliero Universitaria Mater Domini, Catanzaro
Istituto Clinico Humanitas, Milan
Istituto Europeo di Oncologia (IEO), Milan
Ospedale San Raffaele, Milan
Hospital Clínic i Provincial de Barcelona, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Centro Integral Oncologico Clara Campal, Madrid
Hospital General Universitario Gregorio Marañon, Madrid
START Madrid Fundacion Jimenez Diaz, Madrid
Hospital Clínico Universitario Virgen de la Victoria, Málaga
Hospital Universitario Virgen del Rocío, Seville
Velindre Cancer Centre, Cardiff
Sarah Cannon Research Institute UK, London
University College London Hospitals, London
The Christie, Manchester
Lead Sponsor
Menarini Group
INDUSTRY